Who owns ACADIA PHARMACEUTICALS INC (ACAD)? Elite investor 13F holders
4 tracked elite investors reported holding ACADIA PHARMACEUTICALS INC as of 2026-09-30, including D.E. Shaw, Renaissance Technologies LLC, Bridgewater Associates, Gotham Asset Management. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
4 tracked investors currently reported holding · Latest report period: 2026-09-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| D.E. Shaw | ACADIA PHARMACEUTICALS INC | SHARE | 2026-09-30 | 2026-11-16 00:00:00 | 43033911.00 USD | 2135678.000000 | Shares | add | Original filing |
| Renaissance Technologies LLC | ACADIA PHARMACEUTICALS INC | SHARE | 2026-09-30 | 2026-11-12 00:00:00 | 22316044.00 USD | 1107496.000000 | Shares | reduce | Original filing |
| Bridgewater Associates | ACADIA PHARMACEUTICALS INC | SHARE | 2026-09-30 | 2026-11-16 00:00:00 | 984549.00 USD | 48861.000000 | Shares | reduce | Original filing |
| Gotham Asset Management | ACADIA PHARMACEUTICALS INC | SHARE | 2026-09-30 | 2026-11-16 00:00:00 | 297978.00 USD | 14788.000000 | Shares | buy | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.